ClinicaliQ Trial Snapshot
- A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation — Active Not Recruiting • Phase III • Cardiology / Cardiovascular • NCT05757869.
- Milvexian tested against apixaban for preventing stroke and blood clots in atrial fibrillation patients.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The purpose of this study is to evaluate if milvexian is at least as effective as apixaban for reducing the risk of the composite stroke and non-central nervous system (CNS) systemic embolism. Conditions: Atrial Fibrillation Interventions: Milvexian, Apixaban, Placebo, Apixaban Placebo Lead Sponsor: Janssen Research & Development, LLC Planned Enrollment: 20284 participants